This phenomenon was also demonstrated in preclinical animal studies since NASH-HCC mice that were treated with anti-programmed death-1 (PD1)-induced CD8+ T cells did not have tumor regression but rather increased the number and size of the tumor lesions. Here, CD8A is linked to hepatocellular carcinoma.